January 4, 2025 Top High-Yield Dividend Stocks To Watch For 2025
December 22, 2024 What About Federal Reserve Rates Cut?
December 20, 2024 Honda-Nissan Alliance: A Bold Move To Dominate Auto Industry
December 13, 2024 Trump’s Plan: Potential Shake-Up For Bank Regulators
Tesla: High Hopes, Low Deliveries
Nvidia: Don’t Expect Major Gains From Here (Technical Analysis)
3M Company: Laying The Groundwork For Margin Expansion
Pop Goes The Tesla (Our Top Short For 2025)
Apple: A Piece Of This Pie Is Too Expensive For Me
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
December 21, 2024 Best AI Trading & Performance Tools
December 21, 2024 Best Economic Calendars For Traders
December 9, 2024 When to Switch Payroll Solutions and How to Make a Smooth Transition
Bavarian Nordic (BVNRY) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: January 17, 2025 (07:24)
Sector: HealthcareThe share price of Bavarian Nordic A/S (BVNRY) now
Analysts predictions
Full report
This Week
|
Neutral | Opinions: Na |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Bavarian Nordic A/S stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Bavarian Nordic stock price in 2025, 2026, 2027. How much will one Bavarian Nordic share be worth in 2025 - 2027?
When should I take profit in Bavarian Nordic stock? When should I record a loss on Bavarian Nordic stock? What are analysts' forecasts for Bavarian Nordic stock? What is the future of Bavarian Nordic stock? We forecast Bavarian Nordic stock performance using neural networks based on historical data on Bavarian Nordic stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Bavarian Nordic stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Bavarian Nordic shares. This happens once a day.
Historical and forecast chart of Bavarian Nordic stock
The chart below shows the historical price of Bavarian Nordic stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Bavarian Nordic stock price can be found in the table below.
Long-term forecasts by years.
Bavarian Nordic A/S Analysts predictions review
As of now, Panda has combed through 0 analytical articles which are directly related to BVNRY from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 0 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Jan 01, 1970 to Jan 01, 1970.
Bavarian Nordic's Vaccine Breakthrough: A Bullish Leap into 2025 Revenue Potential
In this analytical review of BVNRY stock, Myriam Alvarez presents a compelling argument with a Bullish stance, projecting positive growth and potential opportunities for investors. Alvarez is a well-recognized figure in financial analysis, with 206 publications to her name and nearly two thousand subscribers, indicating a solid following and engagement. As a contributor since 2023, Alvarez has demonstrated a prolific output in a relatively short time, establishing herself as a credible voice in financial discussions. Her authority is considered average, reflecting a reliable and respected perspective without the pretense of infallibility. This combination of a strong track record and consistent publication rate reinforces the validity of her optimistic outlook on BVNRY stock, making this review an essential read for market aficionados.
Key Theses from the Article
- Bavarian Nordic has secured significant vaccine contracts worth approximately $340 million for 2025.
- The company has a diversified vaccine portfolio that targets multiple infectious diseases.
- Collaborations with international health organizations provide revenue opportunities and impose dependency risks.
- Regulatory events, particularly for the chikungunya vaccine, are critical for near-term revenue growth.
- The stock trades at a discount to peers, with favorable growth prospects, making it a speculative buy.
Factors Influencing BVNRY's Stock Price
Secured Vaccine Contracts
The secured $340 million contracts for 2025 provide a substantial revenue base, enhancing financial stability, and investor confidence. This significant revenue projection directly increases the stock's attractiveness and positions it for potential price appreciation.
Diversified Vaccine Portfolio
BVNKF’s portfolio diversification across critical vaccines (e.g., smallpox, rabies, tick-borne encephalitis) strengthens its market position against competitors. This reduces the company's reliance on a single revenue stream, adding resilience and stability to its stock price.
Regulatory Approval of Chikungunya Vaccine
The chikungunya vaccine's regulatory events in 2025 are pivotal for short-term revenue growth, as approval would open new markets and augment BVNKF's revenue streams. Delays or rejections could materially impact stock valuation negatively.
International Health Organization Collaborations
Collaborations with bodies like WHO and Africa CDC expand BVNKF’s global reach, boosting revenue but adding risks due to potential shifts in partnerships. Loss of these collaborations could substantially impact the company's revenue, affecting stock performance.
Valuation Relative to Peers
Trading at a discount relative to peers makes BVNKF an attractive investment if their growth trajectory continues. This valuation discrepancy suggests untapped upside potential, increasing speculative interest in the stock.
Potential Equity Raising
The company's cash runway is approximately one year, which necessitates potential equity raising if margins do not improve. This could dilute existing shareholder value, posing a moderate downside risk to the stock price.
Review the original AnalysisDiversified Resilience: Bavarian Nordic's Path Amid Market Shifts
In this review, we explore the insightful analysis by Stephen Ayers on BVNRY stock, where he articulately maintains a bullish stance. With an impressive track record of 763 publications since 2017, Ayers not only showcases an immense passion for financial analysis but also demonstrates prolific activity, averaging over 150 articles per year. His credibility is notably esteemed, as reflected by his excellent standing among peers, bolstered by a robust subscriber base of 7,556 individuals. Such metrics underscore the trust and influence he commands in the financial community. Readers can anticipate a detailed, authoritative examination from Ayers, whose perspectives continue to shape and inform investor decisions on stocks like BVNRY.
Key Theses of the Review
- Bavarian Nordic's mpox vaccine sales have declined following the initial outbreak, affecting overall revenue.
- The company's Travel Health segment is performing well, showing a 21% increase in revenue year-over-year.
- Bavarian is actively pursuing diversification, including plans for the chikungunya vaccine launch aimed at a growing market.
- The company maintains a strong liquidity position with $262 million in cash and low long-term debt levels.
- Despite current volatility, Bavarian's diversification strategy and global health positioning support a continued 'buy' recommendation for long-term investors.
Factors Influencing BVNRY Stock Price
Mpox Vaccine Sales Decline
The decline in mpox vaccine sales has a significant negative impact on Bavarian's revenue since it highlights the company's reliance on demand driven by outbreaks. This factor represents a high dependence on market conditions related to health emergencies.
Travel Health Segment Performance
The strong growth in the Travel Health segment, with a 21% increase in revenue, indicates potential for stable, non-volatile revenue streams. This factor is pivotal in the company's move towards more predictable revenue sources.
Chikungunya Vaccine Market Potential
Bavarian's focus on launching a chikungunya vaccine positions it for long-term market capture in a field projected to be worth $500 million by 2032. Although significant, its impact depends on successful regulatory approval and market penetration.
Liquidity Position
Bavarian's strong liquidity with $262 million in cash allows it to manage short-term liabilities effectively, adding stability to financial operations. While critical for maintaining operations, its direct impact on stock price may be moderate unless liquidity issues arise.
Geopolitical and Policy Risks
The appointment of a known anti-vaccine advocate in the U.S. health administration introduces uncertainty, potentially affecting public health policy and Bavarian's future government contracts. This represents a high-impact factor affecting investor sentiment and stock price.
Review the original AnalysisCommentary
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Bavarian Nordic daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan 19 | 9.21 | 9.03 | 9.51 | 5.41 |
Jan 20 | 9.02 | 8.91 | 9.17 | 2.89 |
Jan 21 | 8.73 | 8.41 | 9.08 | 8.05 |
Jan 22 | 8.51 | 8.40 | 8.86 | 5.48 |
Jan 23 | 8.78 | 8.45 | 9.09 | 7.54 |
Jan 24 | 9.18 | 8.85 | 9.54 | 7.78 |
Jan 25 | 9.06 | 8.81 | 9.26 | 5.20 |
Jan 26 | 8.89 | 8.63 | 9.10 | 5.41 |
Jan 27 | 8.72 | 8.45 | 8.84 | 4.64 |
Jan 28 | 8.32 | 8.09 | 8.65 | 6.89 |
Jan 29 | 8.42 | 8.32 | 8.65 | 3.94 |
Jan 30 | 8.77 | 8.47 | 9.11 | 7.51 |
Jan 31 | 8.67 | 8.38 | 9.02 | 7.61 |
Feb 01 | 8.63 | 8.35 | 8.78 | 5.12 |
Feb 02 | 8.52 | 8.31 | 8.68 | 4.46 |
Feb 03 | 8.48 | 8.35 | 8.60 | 3.05 |
Feb 04 | 8.67 | 8.54 | 9.00 | 5.44 |
Feb 05 | 8.95 | 8.79 | 9.11 | 3.72 |
Feb 06 | 8.53 | 8.21 | 8.76 | 6.70 |
Feb 07 | 8.57 | 8.28 | 8.77 | 5.84 |
Feb 08 | 8.51 | 8.30 | 8.63 | 4.00 |
Feb 09 | 8.48 | 8.26 | 8.63 | 4.52 |
Feb 10 | 8.33 | 8.13 | 8.48 | 4.31 |
Feb 11 | 8.30 | 8.08 | 8.43 | 4.37 |
Feb 12 | 8.13 | 7.97 | 8.21 | 3.01 |
Feb 13 | 8.34 | 8.21 | 8.64 | 5.23 |
Feb 14 | 8.47 | 8.38 | 8.73 | 4.20 |
Feb 15 | 8.52 | 8.34 | 8.81 | 5.67 |
Feb 16 | 8.69 | 8.40 | 9.02 | 7.45 |
Feb 17 | 8.79 | 8.64 | 9.07 | 4.88 |
Bavarian Nordic Daily Price Targets
Bavarian Nordic Stock Forecast 01-19-2025.
Forecast target price for 01-19-2025: $9.21.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 5.128%.
Pessimistic target level: 9.03
Optimistic target level: 9.51
Bavarian Nordic Stock Forecast 01-20-2025.
Forecast target price for 01-20-2025: $9.02.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 2.805%.
Pessimistic target level: 8.91
Optimistic target level: 9.17
Bavarian Nordic Stock Forecast 01-21-2025.
Forecast target price for 01-21-2025: $8.73.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 7.452%.
Pessimistic target level: 8.41
Optimistic target level: 9.08
Bavarian Nordic Stock Forecast 01-22-2025.
Forecast target price for 01-22-2025: $8.51.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 5.192%.
Pessimistic target level: 8.40
Optimistic target level: 8.86
Bavarian Nordic Stock Forecast 01-23-2025.
Forecast target price for 01-23-2025: $8.78.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 7.008%.
Pessimistic target level: 8.45
Optimistic target level: 9.09
Bavarian Nordic Stock Forecast 01-24-2025.
Forecast target price for 01-24-2025: $9.18.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 7.222%.
Pessimistic target level: 8.85
Optimistic target level: 9.54
BVNRY (BVNRY) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Feb. | 9.09 | 7.74 | 10.12 | 23.52 |
Mar. | 10.56 | 9.12 | 11.87 | 23.13 |
Apr. | 10.07 | 9.57 | 11.16 | 14.26 |
May. | 8.36 | 7.83 | 9.63 | 18.75 |
Jun. | 6.79 | 6.14 | 7.54 | 18.56 |
Jul. | 7.70 | 6.99 | 8.65 | 19.22 |
Aug. | 8.48 | 7.21 | 9.33 | 22.73 |
Sep. | 8.50 | 8.14 | 8.99 | 9.45 |
Oct. | 7.87 | 7.10 | 8.22 | 13.60 |
Nov. | 7.95 | 6.69 | 9.13 | 26.66 |
Dec. | 7.01 | 6.35 | 7.88 | 19.40 |
Bavarian Nordic forecast for this year
Bavarian Nordic Stock Prediction for Feb 2025
An uptrend is forecast for this month with an optimal target price of $9.08752. Pessimistic: $7.74. Optimistic: $10.12
Bavarian Nordic Stock Prediction for Mar 2025
An uptrend is forecast for this month with an optimal target price of $10.5597. Pessimistic: $9.12. Optimistic: $11.87
Bavarian Nordic Stock Prediction for Apr 2025
An downtrend is forecast for this month with an optimal target price of $10.074. Pessimistic: $9.57. Optimistic: $11.16
Bavarian Nordic Stock Prediction for May 2025
An downtrend is forecast for this month with an optimal target price of $8.36138. Pessimistic: $7.83. Optimistic: $9.63
Bavarian Nordic Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $6.78944. Pessimistic: $6.14. Optimistic: $7.54
Bavarian Nordic Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $7.69923. Pessimistic: $6.99. Optimistic: $8.65
Bavarian Nordic Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $8.48455. Pessimistic: $7.21. Optimistic: $9.33
Bavarian Nordic Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $8.50152. Pessimistic: $8.14. Optimistic: $8.99
Bavarian Nordic Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $7.8724. Pessimistic: $7.10. Optimistic: $8.22
Bavarian Nordic Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $7.95113. Pessimistic: $6.69. Optimistic: $9.13
Bavarian Nordic Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $7.01289. Pessimistic: $6.35. Optimistic: $7.88
Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 7.07 | 6.08 | 7.99 | 23.89 |
Feb | 6.77 | 6.34 | 7.48 | 15.22 |
Mar | 7.87 | 7.02 | 8.22 | 14.56 |
Apr | 7.10 | 6.57 | 7.48 | 12.14 |
May | 7.85 | 7.13 | 8.49 | 16.08 |
Jun | 7.74 | 7.43 | 8.39 | 11.44 |
Jul | 7.29 | 6.50 | 7.63 | 14.72 |
Aug | 7.90 | 6.91 | 8.60 | 19.67 |
Sep | 8.00 | 6.72 | 8.96 | 25.00 |
Oct | 8.65 | 7.36 | 9.30 | 20.86 |
Nov | 8.83 | 7.50 | 9.36 | 19.81 |
Dec | 9.52 | 8.87 | 10.33 | 14.18 |
Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 9.88 | 9.27 | 10.73 | 13.63 |
Feb | 9.09 | 7.87 | 9.83 | 19.96 |
Mar | 9.51 | 8.88 | 10.36 | 14.31 |
Apr | 11.14 | 10.12 | 12.43 | 18.64 |
May | 10.23 | 8.67 | 11.78 | 26.39 |
Jun | 9.86 | 8.66 | 10.29 | 15.90 |
Jul | 8.58 | 7.60 | 9.78 | 22.28 |
Aug | 8.47 | 7.19 | 8.81 | 18.46 |
Sep | 7.88 | 7.50 | 8.34 | 10.02 |
Oct | 9.36 | 8.60 | 10.84 | 20.73 |
Nov | 9.76 | 9.05 | 11.18 | 19.02 |
Dec | 10.60 | 9.71 | 11.21 | 13.42 |
Bavarian Nordic information and performance
N/A
Market capitalization of the Bavarian Nordic A/S is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BVNRY shares in the company outstanding by the market price of one share.
EBITDA of Bavarian Nordic is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.
Commentary
Investors have a lot to smile about with Bavarian Nordic's upcoming vaccine contracts, which promise a robust $340 million revenue boost in 2025. This financial padding, accompanied by a diverse vaccine portfolio, positions Bavarian Nordic confidently against competitors, bringing both stability and resilience to its stock price. With such a diverse offering and a strong market position, the company significantly reduces dependency on single revenue streams, adding layers of security to its financial future.
This optimistic scenario is tempered slightly by potential regulatory hurdles and the unpredictability of international partnerships. The upcoming chikungunya vaccine approval is a pivotal moment, with its success likely to further strengthen Bavarian Nordic's market presence. Meanwhile, the company’s current valuation relative to peers suggests that there's a hidden gem waiting to be uncovered, despite hints of potential equity raising that may cloud the horizon. Overall, with an average influence strength aligned towards a bullish trajectory in the coming weeks and sustained into the next month, Bavarian Nordic seems to be on a promising path forward. Potential investors may find this an enticing moment to consider diving in.